Communiqués Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
738,72 ^USD	+1,69 %		-1,80 %	-4,29 %

06/10	Regeneron Pharmaceuticals, Inc. annonce la présentation de nouvelles recherches cliniques au congrès 2026 de la Société européenne d’oncologie médicale	CI
06/10	Regeneron Pharmaceuticals, Inc. : Opinion positive de JPMorgan Chase	ZM

Communiqués

06/10	Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026	GL
01/10	Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)	GL
01/10	Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss	GL
01/10	Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies	GL
24/09	Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026	GL
10/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces	BU
08/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD Law	AQ
04/09	SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces	BU
20/08	Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial	AQ
19/08	Regeneron Announces Investor Conference Presentations	GL
19/08	Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)	GL
03/08	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation	AQ
31/07	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation	GL
30/07	Regeneron: Q2 Earnings Snapshot	AQ
30/07	Regeneron Reports Second Quarter 2026 Financial and Operating Results	GL
21/07	REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law	BU
20/07	REGN EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026	NE
18/07	REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026	NE
16/07	Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit	BU
25/06	Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast	GL
22/06	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	GL
04/06	Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO	GL
28/05	Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak	GL
25/05	Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)	NE
22/05	Regeneron Pharmaceuticals - Lynozyfic Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis	AQ